<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology and side effects of azathioprine when used in rheumatic diseases</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology and side effects of azathioprine when used in rheumatic diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology and side effects of azathioprine when used in rheumatic diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">H Michael Belmont, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA) is an immunosuppressive agent that acts through its effects as an antagonist of purine metabolism, resulting in the inhibition of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein synthesis. It has been used as an immunosuppressive agent for the treatment of a variety of disorders; these include a number of rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), dermatomyositis and polymyositis, systemic sclerosis, and systemic vasculitis; inflammatory bowel disease; the prevention of organ transplant rejection; and for other conditions.</p><p>The pharmacology and adverse effects of AZA, particularly when used in the context of the rheumatic diseases, will be reviewed here. The role of AZA in the management of the different rheumatic diseases and other autoimmune and immune-mediated disorders, and for the prevention and management of transplant rejection, is presented in detail separately in the topic reviews covering the treatment of these individual conditions (see appropriate topic reviews).</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND BIOLOGIC EFFECTS</span></p><p class="headingAnchor" id="H3"><span class="h2">Structure and metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA), the 1-methyl-4-nitro-5-imidazolyl derivative of <a class="drug drug_general" data-topicid="9989" href="/z/d/drug information/9989.html" rel="external">thioguanine</a>, is a purine-mimic antimetabolite [<a href="#rid1">1</a>]. It is well-absorbed from the gastrointestinal tract and has a serum half-life of 0.2 to 0.5 hours and a biologic half-life of approximately 24 hours [<a href="#rid2">2</a>]. AZA is a prodrug, which is approximately 30 percent protein-bound. Forty-five percent of the drug is excreted in the urine, and the remainder is metabolized to its principal metabolite, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP), which is formed by the action of glutathione in red blood cells [<a href="#rid1">1</a>]. The 6-MP is then further metabolized along competing routes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xanthine oxidase-dependent metabolism</strong> – 6-MP undergoes catabolic oxidation to 6-thiouric acid, which is an inactive metabolite. This reaction is catalyzed by xanthine oxidase, which is concentrated in the intestine and liver.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiopurine S-methyltransferase and hypoxanthine phosphoribosyl transferase-dependent metabolism</strong> – 6-MP is also metabolized along an anabolic pathway to several metabolites including 6-methylmercaptopurine (6-MMP), 6-methyl-thioinosine 5'-monophosphate, and 6-thioguanine (6-TG). Two enzymes are responsible for catalyzing these reactions: thiopurine S-methyltransferase (TPMT) and hypoxanthine phosphoribosyl transferase (also termed hypoxanthine-guanine phosphoribosyl transferase [HGPRT]).</p><p></p><p class="bulletIndent1">Additionally, nucleoside triphosphate diphosphatase NUDT15 (nudix hydrolase 15, NUDT15) metabolizes the active thiopurine metabolite thioguanosine triphosphate (TGTP) to inactive thioguanosine monophosphate (TGMP); loss-of-function mutations in the <em>NUDT15</em> gene are associated with increased hematologic toxicity [<a href="#rid3">3,4</a>]. (See <a class="local">'Pharmacogenetics and azathioprine toxicity'</a> below.)</p><p></p><p class="headingAnchor" id="H4155307187"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>AZA, through the effects of 6-MP and its metabolites, causes a reduction in intracellular purine synthesis, which results in decreased numbers of circulating B and T lymphocytes [<a href="#rid5">5,6</a>], reduced immunoglobulin synthesis [<a href="#rid6">6</a>], and diminished interleukin (IL) 2 secretion [<a href="#rid7">7</a>]. This occurs through the intracellular metabolism of 6-MP by HGPRT, which produces thioinosinic and thioguanylic acid. These compounds suppress intracellular inosinic acid synthesis, thereby interfering with adenine and guanine ribonucleotide production and resulting in the effects upon lymphoid cells [<a href="#rid1">1,8</a>]. AZA does not reduce serum levels of IL-6 or soluble IL-2 receptor [<a href="#rid9">9</a>].</p><p>Another pathway that is inhibited by <a class="drug drug_general" data-topicid="9989" href="/z/d/drug information/9989.html" rel="external">thioguanine</a> is the intracellular signaling downstream of the necessary costimulatory binding by CD28 on the surface of CD4+ T cells to CD80 and CD86 (B7-1 and B7-2) molecules on antigen-presenting cells [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology", section on 'CD28, B7, and CTLA4'</a>). Specifically, the metabolite 6-thioguanine triphosphate (6-thio-GTP) diminishes the activity of the small GTPase Rac1 in T lymphocytes. 6-thio-GTP blocks the interaction between Rac1 and its guanosine exchange factor Vav1 and inhibits activation of NF-kappaB and STAT3, thereby inducing apoptosis of activated T lymphocytes [<a href="#rid11">11</a>].</p><p>The inhibition of purine metabolism and induction of T-cell apoptosis both depend upon intracellular metabolites for the antineoplastic and immune-modulating effects of AZA [<a href="#rid12">12</a>]. Therefore, serum drug levels are of little value in monitoring treatment.</p><p class="headingAnchor" id="H644933029"><span class="h1">CONSIDERATIONS DURING TREATMENT</span></p><p class="headingAnchor" id="H4"><span class="h2">Pharmacogenetics and azathioprine toxicity</span><span class="headingEndMark"> — </span>The relative accumulation of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (AZA) metabolites depends upon genetic polymorphisms of the genes for the individual enzymes, including thiopurine S-methyltransferase (TPMT) and nucleoside triphosphate diphosphatase NUDT15 (see <a class="local">'Structure and metabolism'</a> above); hematologic toxicity due to AZA and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP) is predominantly related to the activity of TPMT and/or NUDT15 genetic variants, with the frequency of risk variants differing depending upon genetic background. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a>.)</p><p>Risk variants of TPMT and NUDT15 affect various population groups to different degrees:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TPMT</strong> – Deficiency of thiopurine S-methyltransferase (TPMT), which is responsible for the metabolism of thiopurines, including AZA and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">mercaptopurine</a>, causes 6-MP to be preferentially metabolized toward 6-thioguanine (6-TG) nucleotides, which appears to account for much of the hematologic toxicity related to AZA and 6-MP in some populations; there is large interindividual variability in the activity of TPMT. An inactive metabolite, 6-methylmercaptopurine (6-MMP), is associated with hepatotoxicity.</p><p></p><p class="bulletIndent1">In European and African individuals, inherited TPMT deficiency is the primary genetic cause of thiopurine intolerance; as an example, White Americans show a trimodal distribution, with 89 to 94 percent possessing high enzyme activity, 6 to 11 percent intermediate activity due to heterozygosity at t<em>he TPMT</em> locus, and 0.33 percent low activity [<a href="#rid13">13-16</a>]. However, a unimodal distribution of TPMT activity in various Chinese populations was found, indicating considerable differences between population groups in TPMT activity [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NUDT15</strong> – In contrast to <em>TPMT</em> polymorphisms, <em>NUDT15</em> (nucleoside diphosphate-linked moiety X motif 15, NUDIX 15) variants of concern have been described most often in persons from several Asian populations, as well as in Hispanic individuals [<a href="#rid3">3,4,18,19</a>], although one study from Germany has also reported these variants among individuals described as being of European ancestry [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">The poor metabolizer phenotype for NUDT15 appears in approximately 2 percent of studied East Asian populations, which is more prevalent than the poor metabolizer phenotype of TPMT among Europeans. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a> and <a class="local">'Pharmacology and biologic effects'</a> above.)</p><p></p><p class="bulletIndent1">Variants <em>of NUDT15</em>, particularly<em> NUDT15</em> c.415C&gt;T, have been associated, especially in East Asian populations, with increased risk for hematologic toxicity (eg, leukopenia) with AZA/6-MP [<a href="#rid18">18</a>]. In more limited studies using genetic analyses of ancestry, t<em>he NUDT15 </em>variant was common in East Asian populations and found to a lesser degree in patients from Hispanic populations, but was rare in Europeans and not observed in Africans [<a href="#rid19">19</a>]. Although most reports of toxicity related to NUDT15 polymorphisms have been in patients with inflammatory bowel disease and in acute lymphocytic leukemia, cases have been reported in other disorders, including a Chinese patient with Sjögren's disease [<a href="#rid21">21</a>].</p><p></p><p>Data on other genetic polymorphisms are emerging that may help identify patients at risk for AZA-related adverse effects [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a>.)</p><p class="headingAnchor" id="H2798627966"><span class="h2">TPMT and NUDT15 testing</span><span class="headingEndMark"> — </span>There is uncertainty regarding the benefits of routine testing for thiopurine S-methyltransferase (<em>TPMT</em>; OMIM 187680) or <em>NUDT15</em> (OMIM 615792) deficiency before beginning AZA; both genotyping and functional assays for these enzymes are available commercially. As with <em>TPMT</em>, genotyping for <em>NUDT15</em> polymorphisms has not been universally adopted, and the optimal clinical circumstances in which to perform routine testing are not well defined. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a> and <a class="local">'Pharmacology and biologic effects'</a> above.)</p><p>Although some clinicians routinely perform TPMT and/or NUDT15 testing prior to initiating AZA, the author does not perform such testing but rather initiates therapy at a low dose with close monitoring as the dose is gradually increased. (See <a class="local">'Dose titration and monitoring'</a> below.)</p><p>Variation in the <em>TPMT</em> gene can result in functional inactivation of the enzyme and in a markedly increased risk of life-threatening myelosuppression. For this reason, the US Food and Drug Administration (FDA) recommends that "consideration be given to either genotype or phenotype patients for TPMT" prior to treatment with AZA. However, <em>TPMT</em> genotyping has not been universally adopted, and the cost effectiveness and optimal clinical circumstances in which to perform routine testing are not well-defined. Poor metabolizing <em>TPMT</em> gene variants are uncommon among East Asian populations when compared with <em>NUDT15</em> variants. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a> and <a class="local">'Pharmacogenetics and azathioprine toxicity'</a> above.)</p><p>Expert opinions differ regarding the role of <em>TPMT</em> or <em>NUDT15</em> genotyping prior to the administration of thiopurines for treatment of inflammatory and autoimmune disorders. In one study, among patients who developed hematologic toxicity within three months of treatment, 53 percent could be attributed to <em>TPMT</em> and/or <em>NUDT15</em> polymorphisms, but 38 percent remained unexplained [<a href="#rid20">20</a>]. Therefore, some advocate routine testing, while others disagree with this approach, based upon the low frequency of homozygous variants among patients of White European genetic background, low frequency of any genetic risk across all races and ethnicities, the risk of a false sense of security that may arise with testing, and that there are many patients who develop myelosuppression while taking AZA who do not have detectable <em>TPMT </em>or<em> NUDT15</em> gene variants. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a> and <a class="local">'Pharmacology and biologic effects'</a> above.)</p><p>Examples of the clinical observations regarding such testing include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In 1 study among 67 patients given AZA, 5 of 6 individuals heterozygous for a mutant allele (as assessed by polymerase chain reaction-based assays) discontinued therapy within 1 month of drug initiation because of low leukocyte counts [<a href="#rid24">24</a>]. AZA was given for a significantly longer period to those with wild-type alleles compared with patients with gene variants (39 versus 2 weeks, respectively). By contrast, there was no association between <em>TPMT</em> alleles and AZA toxicity in a study of 342 patients with systemic lupus erythematosus (SLE) in Korea [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar considerations to those with AZA apply to the use of 6-MP. In a series of 180 children with acute lymphoblastic leukemia, the cumulative incidence of dose reductions in 6-MP due to drug toxicity was 7 percent in the 161 children with 2 wild-type <em>TPMT</em> alleles, 35 percent in the 17 children with 1 variant allele, and 100 percent in the 2 children with 2 variant alleles [<a href="#rid26">26</a>]. Lowering the 6-MP dose in the last 2 groups permitted administration of the full protocol.</p><p></p><p>Target serum levels of the metabolite 6-TG can provide information to help predict efficacy and toxicity. In an open-label study of AZA therapy for 50 patients with active SLE, pretreatment TPMT status facilitated dosing of AZA necessary to achieve appropriate serum levels of 6-TG [<a href="#rid27">27</a>]. However, this observation requires further validation and more readily available testing for 6-TG levels before it can be applied to routine clinical practice.</p><p class="headingAnchor" id="H6102133"><span class="h2">Drug interactions</span></p><p class="headingAnchor" id="H2696869897"><span class="h3">Xanthine oxidase inhibitors</span><span class="headingEndMark"> — </span>The major drug interactions with AZA are with <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> and <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a>, which slow the elimination of 6-MP by inhibiting xanthine oxidase, the mechanism by which allopurinol and febuxostat reduce uric acid levels in patients with hyperuricemia and gout, consequently increasing the risk of adverse effects from use of AZA [<a href="#rid28">28</a>].</p><p>Thus, the dose of AZA should be reduced significantly (by 50 to 75 percent) in patients who require treatment with <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, but this combination should be avoided if possible. In patients receiving both agents, the white blood cell count should be carefully monitored. When AZA is combined with either xanthine oxidase inhibitor (even with appropriate dose reduction), a complete blood count (CBC) should be performed at two weeks and monthly for three months, and this testing regimen should be repeated any time the dose is increased. TPMT and NUDT15 testing are recommended for patients in populations likely to be at increased risk of genetic variants conveying greater risk of toxicity (see <a class="local">'Pharmacogenetics and azathioprine toxicity'</a> above) when receiving a combination of AZA with allopurinol or <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a>, and an alternative agent should be considered in the setting of heterozygous or homozygous deficiency.</p><p>There is insufficient experience combining AZA and <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a> to make specific dosing reduction recommendations; this combination should be avoided [<a href="#rid29">29</a>]. (See <a class="local">'Bone marrow suppression'</a> below.)</p><p class="headingAnchor" id="H3790146925"><span class="h3">Other medications</span><span class="headingEndMark"> — </span>Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. This tool can also be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. (See  <a class="drug drug_general" href="/z/d/drug information/9026.html" rel="external">"Azathioprine: Drug information"</a>.)</p><p class="headingAnchor" id="H572551042"><span class="h2">Dose titration and monitoring</span><span class="headingEndMark"> — </span>For most rheumatic disease indications, we generally use an initial dose of AZA of 25 to 50 mg/day, and we obtain a CBC after two weeks of therapy to ensure that the counts are stable because toxicity can be seen even at low doses. We then usually increase the daily dose by 50 mg (or approximately 0.5 mg/kg/day) every four weeks to 1.5 mg/kg/day. In patients with a higher target dose for a given medical condition or with an inadequate response after three months of therapy, we increase the dose as tolerated up to a maximum typically of 3 mg/kg/day. A lower dose is indicated in patients with renal insufficiency. For dose adjustment in kidney impairment, refer to the drug information for <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> included within UpToDate.</p><p>A CBC and platelet count should be monitored every two weeks during dose escalation and every four to six weeks after a stable dose is achieved. Some experts suggest liver enzyme testing every six to eight weeks during AZA therapy. For patients on a stable testing routine, surveillance testing may be reduced after the first year to every three months.</p><p>In patients who develop leukopenia (white blood cells &lt;4000/microL) or thrombocytopenia (platelet count &lt;150,000/microL) during therapy, the AZA dose should be reduced by 50 percent or the drug should be discontinued. If a 50 percent reduction in the dose is associated with persistent cytopenia, then AZA should generally be permanently discontinued. Patients who develop macrocytosis should be closely monitored with more frequent CBCs (eg, initially every two weeks for a month) once other major causes of macrocytosis have been excluded, including vitamin B12 and folate deficiency. Stable mild macrocytosis in the absence of vitamin deficiency is a potential side effect that is well-tolerated and does not require discontinuation of medication.</p><p class="headingAnchor" id="H2883424937"><span class="h2">Reproductive health concerns</span><span class="headingEndMark"> — </span>AZA can generally be continued during pregnancy in patients with rheumatic disease and does not appear to reduce male fertility. The evidence and recommendations are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Azathioprine and 6-mercaptopurine'</a> and  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H989213717"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Although the frequency of toxicity in patients with rheumatic diseases treated with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (AZA) is comparable with that of other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, AZA must still be administered with caution [<a href="#rid2">2,30,31</a>].</p><p>The most common side effects of AZA at doses typically used in the treatment of rheumatic diseases include gastrointestinal intolerance, bone marrow suppression, and infection. (See <a class="local">'Gastrointestinal'</a> below and <a class="local">'Bone marrow suppression'</a> below and <a class="local">'Infection'</a> below.)</p><p>Other concerns include malignancy and risks related to increased drug levels with the concomitant use of xanthine oxidase inhibitors. (See <a class="local">'Malignancy risk'</a> below and <a class="local">'Reproductive health concerns'</a> above and <a class="local">'Xanthine oxidase inhibitors'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Anorexia, nausea, and vomiting occur in up to 23 percent of patients treated with AZA; these symptoms usually begin soon after the initiation of therapy [<a href="#rid14">14</a>]. In contrast to hematologic toxicity, TPMT deficiency or <em>NUDT15</em> variants are poor predictors of gastrointestinal side effects. In our experience, starting the AZA at a low dose sometimes abrogates the nausea and vomiting. By comparison, diarrhea occurs in less than 1 percent of patients, and a mild elevation of liver enzymes occurs in approximately 5 percent. Progression to cirrhosis has not been described [<a href="#rid2">2</a>].</p><p>Dramatic gastrointestinal hypersensitivity reactions have been reported in a few patients, characterized by nausea, vomiting, and often diarrhea and fever. Other nonspecific symptoms that should alert the clinician to this hypersensitivity syndrome include rash, myalgias, malaise, elevation of liver enzymes, and occasional hypotension, all occurring within the first few weeks of therapy.</p><p>Drug-induced pancreatitis is a rare adverse effect of AZA and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP) [<a href="#rid32">32,33</a>]; evidence from patients with inflammatory bowel disease suggests that increased risk of this side effect is associated with the presence of specific human leukocyte antigen (HLA) class II variants, with an association seen in these patients with the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype [<a href="#rid34">34</a>]. AZA-induced pancreatitis is less frequently reported in autoimmune rheumatic connective tissue diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), than in inflammatory bowel disease or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [<a href="#rid33">33,35</a>].</p><p class="headingAnchor" id="H2022036553"><span class="h2">Hematologic complications and malignancies</span></p><p class="headingAnchor" id="H9"><span class="h3">Bone marrow suppression</span><span class="headingEndMark"> — </span>Dose-related marrow suppression results in leukopenia in up to 27 percent of patients and thrombocytopenia in up to 5 percent [<a href="#rid2">2,14</a>]. Mild leukopenia usually responds to a reduction in the daily dose of AZA, which is done mostly when the absolute neutrophil count is less than 1000 cells/microL and/or the absolute lymphocyte count (ALC) is less than 600 cells/microL [<a href="#rid2">2</a>]. Use of AZA in addition to glucocorticoids with a low ALC is a risk factor for opportunistic infections such as <em>Pneumocystis jirovecii</em> pneumonia (PCP), and on a case-by-case basis, a decision is required to determine if the risk is warranted and if antibiotic prophylaxis is appropriate. Thrombocytopenia occurs in up to 5 percent of patients [<a href="#rid14">14</a>]. Unless platelets are below 50,000/microL, which is uncommon, clinical bleeding or need for concurrent antiplatelet drug therapy dose reduction is typically not required.</p><p>Genetically determined abnormalities that reduce thiopurine S-methyltransferase (TPMT) and nucleoside triphosphate diphosphatase NUDT15 (NUDT15) may reduce AZA metabolism and result in a significant risk for myelosuppression and a macrocytic anemia [<a href="#rid14">14,15,36</a>]. (See <a class="local">'Pharmacogenetics and azathioprine toxicity'</a> above.)</p><p>The risk of AZA accumulation and possibly severe bone marrow toxicity is much greater when AZA is given with <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> [<a href="#rid37">37</a>] or <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a>. As a result, we generally <strong>avoid</strong> this combination. Dose reduction and close monitoring are required if it is necessary to use these drugs together. (See <a class="local">'Xanthine oxidase inhibitors'</a> above.)</p><p class="headingAnchor" id="H1615865564"><span class="h3">Malignancy risk</span><span class="headingEndMark"> — </span>There is some evidence suggesting a possible but small increased risk of malignancy in patients with rheumatoid arthritis treated with AZA [<a href="#rid5">5,38,39</a>]. However, in one study, a trend for an increase in risk of hematologic malignancy compared with control patients not treated with AZA was no longer significant after adjusting for confounding variables, including other drug therapies [<a href="#rid38">38</a>]. In another study, with a 20-year follow-up of patients with rheumatoid arthritis treated with 300 mg daily of AZA, the absolute increase in risk for lymphoproliferative malignancy with the drug was estimated at 1 case per 1000 patient-years of exposure [<a href="#rid39">39</a>]. The study could not exclude an increased risk of other cancers, but no dose-dependent or site-specific increase was seen in the cases identified. One report has described a possible increase in hematologic malignancies in patients with SLE exposed to immunosuppressive agents, although the increase was not limited to patients receiving AZA [<a href="#rid40">40</a>].</p><p>Although an initial report appeared to show an increased risk of neoplasms in patients with rheumatoid arthritis using AZA [<a href="#rid41">41</a>], a subsequent study found that high rheumatoid arthritis disease activity conferred greater risk of lymphoma than did treatment [<a href="#rid42">42</a>].</p><p>The risk of malignancy is much higher, by comparison, in patients being treated to prevent organ transplant rejection. Renal transplant recipients who have been treated with protocols including AZA have demonstrated a 50- to 100-fold increase in the relative risk of malignant disease [<a href="#rid5">5,43</a>]. The most common tumors are squamous cell carcinomas of the skin, non-Hodgkin lymphoma, Kaposi sarcoma, in situ carcinomas of the uterine cervix, and carcinomas of the vulva and perineum [<a href="#rid43">43</a>]. Skin cancer is most common, occurring in 20 to 37 percent of patients, depending in part upon sun exposure. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p>One study using mutational signature analysis revealed an association between the presence of a novel signature (signature 32) and cutaneous squamous cell carcinoma in patients with chronic exposure to AZA [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infections occur overall in up to 9 percent of patients [<a href="#rid2">2,5</a>]. Bacterial infections usually occur in the clinical setting of leukopenia [<a href="#rid45">45,46</a>]. Viral infections, especially herpes zoster, occur in up to 6 percent of treated patients [<a href="#rid5">5,46</a>]. Exacerbation of chronic viral hepatitis may also occur [<a href="#rid47">47</a>]. There are no established guidelines to indicate the severity or frequency of infection(s) that necessitates discontinuing AZA, and this decision should be determined on an individual basis, depending upon the severity of the infection, comorbidities, other medications, and general medical status.</p><p>Patients who will receive AZA should receive appropriate immunizations to help prevent infectious complications. Recommendations may be affected by the underlying illness and other medications being employed  (<a class="graphic graphic_table graphicRef119665" href="/z/d/graphic/119665.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p class="headingAnchor" id="H3560951495"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H1122252"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA) is a derivative of <a class="drug drug_general" data-topicid="9989" href="/z/d/drug information/9989.html" rel="external">thioguanine</a>, a purine-mimic antimetabolite, which is well-absorbed from the gastrointestinal tract. AZA is a prodrug; the action of glutathione in red blood cells causes the formation of the principal metabolite, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP). The prodrug AZA is approximately 30 percent protein-bound, and 45 percent of the drug is excreted in the urine; the remainder is metabolized to 6-MP, which is then further metabolized. (See <a class="local">'Structure and metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The metabolism of 6-MP is by competing routes: catabolic oxidation to 6-thiouric acid, which is catalyzed by xanthine oxidase, and metabolism along an anabolic pathway to several metabolites, for which two enzymes are responsible: thiopurine S-methyltransferase (TPMT) and hypoxanthine-guanine phosphoribosyl transferase (HGPRT). (See <a class="local">'Structure and metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relative accumulation of 6-MP metabolites depends upon genetic polymorphisms of several enzymes. The toxicity of AZA and 6-MP is substantially affected by the activity of TPMT. Deficiency of this enzyme causes 6-MP to be preferentially metabolized toward 6-thioguanine (6-TG) nucleotides, which appear to account for much of the toxicity related to 6-MP. Depending upon the ethnicity, low TPMT activity has been observed in up to 11 percent of the population, with 0.3 percent having negligible activity. Analysis of the <em>TPMT</em> gene by use of commercially available genotyping or functional assays for the enzyme prior to the administration of AZA may help predict those individuals at risk for severe toxicity. Other genes (eg, <em>NUDT15</em> genetic variants in East Asian and Hispanic populations) also have a role in determining and predicting AZA toxicity. (See <a class="local">'Pharmacogenetics and azathioprine toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracellular metabolites of 6-MP are responsible for a reduction in intracellular purine synthesis and for the antineoplastic and immune-modulating effects of AZA. Serum drug levels are, therefore, of little value in monitoring treatment. AZA causes decreased numbers of circulating B and T lymphocytes, reduced immunoglobulin synthesis, diminished interleukin (IL) 2 secretion, and inhibition of the intracellular signaling downstream of T-cell costimulation involving CD28-mediated pathways. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major drug interaction with AZA is with <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> and <a class="drug drug_general" data-topicid="9079" href="/z/d/drug information/9079.html" rel="external">febuxostat</a>, which slow the elimination of 6-MP by inhibiting xanthine oxidase. Thus, the dose of AZA needs to be reduced significantly (50 to 75 percent) in patients treated with allopurinol, but this combination should be avoided if possible. Use of AZA with febuxostat should also be avoided. (See <a class="local">'Xanthine oxidase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the treatment of rheumatic diseases, AZA is generally begun at a dose of 25 to 50 mg/day for two weeks to test for drug hypersensitivity and serve as a screen for <em>TPMT</em> homozygous deficiency and other causes of diminished AZA/6-MP metabolism. The dose is then increased incrementally by 0.5 mg/kg/day every four weeks until the desired response is seen or until a maximal total dose of 3 mg/kg/day is reached. A lower dose is indicated in patients with renal insufficiency. (See <a class="local">'Dose titration and monitoring'</a> above and <a class="local">'TPMT and NUDT15 testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood count (CBC) and platelet count should be monitored every two weeks during dose escalation and every four to six weeks after a stable dose is achieved. Some experts suggest liver enzyme testing every six to eight weeks during AZA therapy. The AZA dose should be reduced or discontinued in patients who develop leukopenia or thrombocytopenia. Patients who develop macrocytosis should be more closely monitored once the usual causes, such as vitamin B12 deficiency, have been excluded. After one year on a stable dosing routine, surveillance laboratory testing can be reduced to every three months. (See <a class="local">'Dose titration and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of toxicity of AZA in patients with rheumatoid arthritis and other rheumatic diseases is comparable with that of other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and AZA must be administered with great caution. The most common side effects of AZA at doses typically used in the treatment of rheumatic diseases include gastrointestinal intolerance, bone marrow suppression, and infection. The increase in relative risk of malignancy in patients with rheumatoid arthritis is small in contrast with the effects of AZA in renal transplant recipients. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H2043977"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge William Wilke, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Elion GB. The purine path to chemotherapy. Science 1989; 244:41.</a></li><li><a class="nounderline abstract_t">Huskisson EC. Azathioprine. Clin Rheum Dis 1984; 10:325.</a></li><li><a class="nounderline abstract_t">Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019; 105:1095.</a></li><li><a class="nounderline abstract_t">Moyer AM. NUDT15: A bench to bedside success story. Clin Biochem 2021; 92:1.</a></li><li class="breakAll">McKendry RJR. Pruine analogues. In: Second Line Agents in the Treatment of Rheumatic Diseases, Dixon J, Furst BE (Eds), Marcel Decker, New York 1991.</li><li><a class="nounderline abstract_t">Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 1982; 306:365.</a></li><li><a class="nounderline abstract_t">Bacon PA, Salmon M. Modes of action of second-line agents. Scand J Rheumatol Suppl 1987; 64:17.</a></li><li><a class="nounderline abstract_t">Elion GB, Hitchings GH. Azathioprine. Handbook Exp Pharmacol 1975; 38:404.</a></li><li><a class="nounderline abstract_t">Crilly A, McInnes IB, Capell HA, Madhok R. The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. Scand J Rheumatol 1994; 23:87.</a></li><li><a class="nounderline abstract_t">Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133.</a></li><li><a class="nounderline abstract_t">Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176:640.</a></li><li><a class="nounderline abstract_t">Nyhan WL, Sweetman L, Carpenter DG, et al. Effects of azathiprine in a disorder of uric acid metabolism and cerebral function. J Pediatr 1968; 72:111.</a></li><li><a class="nounderline abstract_t">Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149.</a></li><li><a class="nounderline abstract_t">Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651.</a></li><li><a class="nounderline abstract_t">Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982; 222:174.</a></li><li><a class="nounderline abstract_t">McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55:15.</a></li><li><a class="nounderline abstract_t">Zhang JP, Zhou SF, Chen X, Huang M. Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. Clin Chim Acta 2006; 365:337.</a></li><li><a class="nounderline abstract_t">Zhang AL, Yang J, Wang H, et al. Association of NUDT15 c.415C&gt;T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis. Ir J Med Sci 2018; 187:145.</a></li><li><a class="nounderline abstract_t">Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015; 33:1235.</a></li><li><a class="nounderline abstract_t">Schaeffeler E, Jaeger SU, Klumpp V, et al. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med 2019; 21:2145.</a></li><li><a class="nounderline abstract_t">Fei X, Shu Q, Hua BZ, et al. NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review. Medicine (Baltimore) 2018; 97:e0301.</a></li><li><a class="nounderline abstract_t">Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:57.</a></li><li><a class="nounderline abstract_t">Dickson AL, Daniel LL, Jackson E, et al. Race, Genotype, and Azathioprine Discontinuation : A Cohort Study. Ann Intern Med 2022; 175:1092.</a></li><li><a class="nounderline abstract_t">Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716.</a></li><li><a class="nounderline abstract_t">Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23:873.</a></li><li><a class="nounderline abstract_t">Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001.</a></li><li><a class="nounderline abstract_t">Askanase AD, Wallace DJ, Weisman MH, et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 2009; 36:89.</a></li><li><a class="nounderline abstract_t">Kaczmorski S, Doares W, Winfrey S, et al. Gout and transplantation: new treatment option-same old drug interaction. Transplantation 2011; 92:e13.</a></li><li class="breakAll">US Food and Drug Administration. Uloric (febuxostat tablets). Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm243770.htm (Accessed on May 06, 2014).</li><li><a class="nounderline abstract_t">Currey HL, Harris J, Mason RM, et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J 1974; 3:763.</a></li><li><a class="nounderline abstract_t">Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 2017; 76:1575.</a></li><li><a class="nounderline abstract_t">Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39:709.</a></li><li><a class="nounderline abstract_t">van Geenen EJ, de Boer NK, Stassen P, et al. Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon. Aliment Pharmacol Ther 2010; 31:1322.</a></li><li><a class="nounderline abstract_t">Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46:1131.</a></li><li><a class="nounderline abstract_t">Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20:843.</a></li><li><a class="nounderline abstract_t">Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 1982; 20:637.</a></li><li><a class="nounderline abstract_t">Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34:2246.</a></li><li><a class="nounderline abstract_t">Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378.</a></li><li><a class="nounderline abstract_t">Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47:988.</a></li><li><a class="nounderline abstract_t">Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008; 67:74.</a></li><li><a class="nounderline abstract_t">Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26:1705.</a></li><li><a class="nounderline abstract_t">Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008; 8:87.</a></li><li><a class="nounderline abstract_t">Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.</a></li><li><a class="nounderline abstract_t">Inman GJ, Wang J, Nagano A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun 2018; 9:3667.</a></li><li><a class="nounderline abstract_t">Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol 1976; 3:140.</a></li><li><a class="nounderline abstract_t">Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989; 32:837.</a></li><li><a class="nounderline abstract_t">Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18:363.</a></li></ol></div><div id="topicVersionRevision">Topic 7994 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649979" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The purine path to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6509884" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30447069" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : NUDT15: A bench to bedside success story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675810" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : NUDT15: A bench to bedside success story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6459531" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Azathioprine decreases suppressor T cells in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124265" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Modes of action of second-line agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Azathioprine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165444" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697733" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365460" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5634933" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of azathiprine in a disorder of uric acid metabolism and cerebral function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2758725" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7191632" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7086699" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299312" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thiopurine methyltransferase activity in American white subjects and black subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16223474" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28470355" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of NUDT15 c.415C&gt;T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25624441" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30728528" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702976" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206640" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35724382" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Race, Genotype, and Azathioprine Discontinuation : A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841604" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396707" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580024" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040311" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21792048" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gout and transplantation: new treatment option-same old drug interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21792048" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gout and transplantation: new treatment option-same old drug interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4606370" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450313" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16082282" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drug-induced pancreatitis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20222913" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217962" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15479355" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7138494" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thiopurine methyltransferase biochemical genetics: human lymphocyte activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843532" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effect of 6-mercaptopurine and allopurinol on granulopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299492" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3207388" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545189" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451066" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501101" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247108" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cancers complicating organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30202019" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/950630" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2751718" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895374" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
